Alphyn’s AB-101 Platform contains multiple bioactive compounds to power a new class of therapeutics capable of attacking disease in numerous ways. This unique approach and platform produce Multi-Target Therapeutics that target multiple diseases as well as multiple symptoms and causes of individual diseases.
AB-101a is in development to uniquely solve the critical challenges associated with treating mild-to-moderate atopic dermatitis (AD), the most common form of eczema. Developed with our proprietary, multi-target AB-101 Platform, AB-101a is a steroid-free topical with the potential to offer the first complete therapeutic for AD, treating both the immune system and bacterial components of the disease. A Phase 2a clinical trial evaluating AB-101a in adults and children, starting at age 2, is underway. The first cohort has been completed, meeting all primary endpoints.
